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Abstract
 
The c-Jun NH
 
2
 
-terminal kinase (JNK) signaling pathway is induced by cytokines and stress
stimuli and is implicated in cell death and differentiation, but the specific function of this path-
way depends on the cell type. Here we examined the role of JNK1 and JNK2 in CD8
 
 
 
 T cells.
Unlike CD4
 
 
 
 T cells, the absence of JNK2 causes increased interleukin (IL)-2 production and
proliferation of CD8
 
 
 
 T cells. In contrast, JNK1-deficient CD8
 
 
 
 T cells are unable to undergo
antigen-stimulated expansion in vitro, even in the presence of exogenous IL-2. The hypopro-
liferation of these cells is associated with impaired IL-2 receptor 
 
 
 
 chain (CD25) gene and cell
surface expression. The reduced level of nuclear activating protein 1 (AP-1) complexes in acti-
vated JNK1-deficient CD8
 
 
 
 T cells can account for the impaired IL-2 receptor 
 
 
 
 chain gene
expression. Thus, JNK1 and JNK2 play different roles during CD8
 
 
 
 T cell activation and these
roles differ from those in CD4
 
 
 
 T cells.
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Introduction
 
CD4
 
 
 
 and CD8
 
 
 
 T cells are two subsets of peripheral T
cells that play important yet distinct roles during an immune
 
response. After antigen stimulation, CD4
 
 
 
 T cells differen-
tiate into effector Th1 or Th2 cells that secrete cytokines to
help modulate the type of immune response that develops.
 
Th1 cells promote cell-mediated immunity against intracellu-
lar microbial pathogens whereas Th2 cells promote humoral
immunity against parasites and extracellular pathogens.
 
CD8
 
 
 
 T cells differentiate into cytotoxic T (Tc)
 
*
 
 cells to
help defend the host during the cell-mediated immune re-
sponse. Tc cells secrete high levels of cytokines, mainly
 
IFN-
 
 
 
, and have cytotoxic activities that are mediated by
secreted proteins such as perforin and granzyme (1). Thus,
in addition to the balance between Th1 and Th2 differenti-
ation, impaired or enhanced CD8
 
 
 
 T cell activation and
differentiation play crucial roles in the susceptibility or re-
sistance of the host to intracellular pathogens.
During the activation and differentiation of CD4
 
 
 
 and
CD8
 
 
 
 T cells, a substantial reprogramming of gene ex-
pression occurs ultimately giving these cells the ability to
perform their effector functions. To date, many studies
have identified and characterized transcription factors and
signal transduction pathways that regulate CD4
 
 
 
 T cell ac-
tivation and differentiation. Little is known about molecu-
lar mechanisms and signaling pathways that control these
events in CD8
 
 
 
 T cells. The divergent functions of CD4
 
 
 
and CD8
 
 
 
 T cells suggest that distinct signaling require-
ments and molecular mechanisms exist for each subset.
Signal transduction via mitogen-activated protein (MAP)
kinases is involved in a variety of cellular responses, includ-
ing growth factor–induced proliferation, differentiation,
and cell death. Several parallel MAP kinase signal transduc-
tion pathways have been defined in mammalian cells and
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2
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mitogen-activated protein; MKK, MAP kinase kinase; NF, nuclear factor;
NFAT, nuclear factor of activated T cells; RPA, ribonuclease protection
assay; Tc, cytotoxic T; TUNEL, terminal deoxynucleotidyltransferase-
mediated dUTP nick end-labeling. 
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implicated in the control of the immune response (2–4).
These pathways include the extracellular signal–regulated
kinases (ERKs) (5, 6), c-Jun NH
 
2
 
-terminal kinases (JNKs,
also known as SAPKs) (7, 8), and p38 MAP kinases (9–11).
JNK, like the other MAP kinases, requires dual phos-
phorylation of threonine and tyrosine residues within the
protein kinase subdomain VIII by MAP kinase kinases
(MKKs). MKK4 (SEK1) and MKK7 phosphorylate JNK
in response to environmental stress and mitogenic factors
(12–17). While MKK7 specifically regulates JNK, MKK4
has been shown to also activate p38 MAP kinase (12, 18).
Mice deficient for either MKK4 or MKK7 are embryonic
lethal (19–22). Interestingly, studies of 
 
Mkk4
 
 
 
/
 
 
 
, 
 
Mkk7
 
 
 
/
 
 
 
,
or 
 
Mkk4
 
 
 
/
 
 
 
Mkk7
 
 
 
/
 
 
 
 murine embryonic fibroblasts have
shown that MKK4 and MKK7 differentially regulate the
JNK signal transduction pathway (17). In addition, studies
of chimeric mice containing either MKK4 or MKK7-defi-
cient CD4
 
 
 
 T cells have shown that both of these kinases
are required for the normal functioning of peripheral T
cells (19–21). Recently, it has been shown that 
 
Mkk7
 
 
 
/
 
 
 
chimeric mice also have dramatic B cell and mast cell
abnormalities (22). Together these studies support the
critical role of the JNK signaling pathway in the immune
response.
Within the JNK group of MAP kinases, three genes have
been identified, 
 
Jnk1
 
, 
 
Jnk2
 
, and 
 
Jnk3
 
 (2, 4). In addition, 10
isoforms generated by alternative splicing have been identi-
fied. Each isoform differs in its interaction with specific
substrates, such as c-Jun, Elk-1, and ATF2 (23). JNK has
also been shown to phosphorylate and regulate the tran-
scription activities of JunB (24) and nuclear factor of acti-
vated T cells (NFAT) (25, 26). 
 
Jnk3
 
 is selectively expressed
in heart, brain, and testis, whereas 
 
Jnk1
 
 and 
 
Jnk2
 
 are consti-
tutively expressed in many tissues, except spleen and lymph
nodes (27, 28). Recent studies have shown that 
 
Jnk1
 
 and
 
Jnk2
 
 gene expression is induced in peripheral CD4
 
 
 
 T cells
after in vitro and in vivo activation (28). In T cells a co-
stimulatory signal mediated by CD28 is required to induce
JNK activity (28, 29). Activation of JNK in thymocytes ap-
pears to be required for negative selection (30–33). Studies
using mice deficient of 
 
Jnk2
 
 or 
 
Jnk1
 
 have shown that JNK2
is required for IFN-
 
 
 
 production by peripheral CD4
 
 
 
 T
cells and subsequent Th1 differentiation in vitro (34)
whereas JNK1 appears to be a negative regulator of Th2
differentiation in vitro (35). In correlation, mice deficient
for 
 
Jnk1
 
 are unable to resolve 
 
Leishmania major
 
 infections in
vivo due to predominant Th2 responses (36). Mice defi-
cient for both 
 
Jnk1
 
 and 
 
Jnk2
 
 are embyronic lethal due to
increased cell death in the developing forebrain (37, 38).
Recent studies of chimeric mice containing 
 
Jnk1
 
 
 
/
 
 
 
Jnk2
 
 
 
/
 
 
 
compound mutant CD4
 
 
 
 T cells confirm that JNK is re-
quired for effector function but not for CD4
 
 
 
 T cell acti-
vation (21). In contrast, other groups using total T cells
from JNK2 (31) or JNK1-deficient mice (32) have shown
that the JNK signaling pathway is required for T cell acti-
vation and IL-2 production.
In this study, we have examined the role of the JNK
signaling pathway in CD8
 
 
 
 T cell function. Activated
 
CD8
 
 
 
 T cells that lack JNK2 hyperproliferate due to in-
creased IL-2 production whereas activated CD8
 
 
 
 T cells
that lack JNK1 hypoproliferate due to reduced expression
of the 
 
 
 
 chain of the IL-2 receptor. These results therefore
indicate that JNK1 and JNK2 have distinct roles in CD8
 
 
 
T cell activation.
 
Materials and Methods
 
Mice. Jnk1
 
 
 
/
 
 
 
 and 
 
Jnk2
 
 
 
/
 
 
 
 mice have been described previ-
ously (34, 35). These mice are on the C57BL/6 background (The
Jackson Laboratory). The animal infection procedures used in this
study were approved by the Wellington School of Medicine An-
imal Ethics Committee and performed in accordance with the
guidelines of the University of Otago, New Zealand. All other
procedures performed on the animals used in this study are in ac-
cordance with the institutional guidelines of the Animal Care Fa-
cility at the University of Vermont.
 
Virus Infection.
 
The A/HKx31 (H3N2) influenza A virus is a
laboratory-generated recombinant with the external surface com-
ponents of A/Aichi/2/68 (H3H2) and the internal components
of A/PR8/8/34 (H1N1) (39). Virus stocks were grown and viral
titers were determined as described previously (40). Mice were
anesthetized with an intraperitoneal injection of a mixture of ket-
amine and xylazine (Phoenix) and 12 hemagglutination units of
virus were administered by intranasal inoculation.
Virus titers in the lung tissue of infected mice were determined
using the Madin-Darby kidney cell assay as described previously
(40). Virus titers were graphed by interpolation of the last dilu-
tion that showed hemagglutination.
Antibody production in infected mice was measured by ELISA
using purified Influenza HKx31 antigen (10 
 
 
 
g/ml; SPAFAS) as
described previously (41).
 
Cell Preparation and Surface Staining.
 
Total CD8
 
 
 
 T cells were
isolated from spleen and lymph nodes by negative selection using
anti-NK 1.1 (BD PharMingen), anti-CD4 (GK 1.5), anti-Mac1
(BD PharMingen), and anti-MHC class II mAbs followed by de-
pletion with magnetic beads (PerSeptive Biosystems) as described
previously (42–44). Total CD4
 
 
 
 T cells were similarly isolated
from spleen and lymph nodes with anti-NK1.1, anti-CD8, anti-
Mac1, and anti-MHC class II mAbs. CD8
 
 
 
 or CD4
 
 
 
 T cells (10
 
6
 
cells/ml) were activated with plastic-immobilized anti-CD3
(2C11; 5 
 
 
 
g/ml) in the presence or absence of soluble anti-
CD28 mAb (1 
 
 
 
g/ml; BD PharMingen), IL-2 (50 U/ml; R&D
Systems), and anti-IL-2 mAbs (10 
 
 
 
g/ml; BD PharMingen).
Expression of IL-2R
 
 
 
 (CD25) was determined by cell surface
staining and flow cytometry (EPICS; Coulter), using a cy-
chrome-conjugated anti-CD8 mAb and a PE-conjugated anti-
CD25 mAb (BD PharMingen).
 
Proliferation and Measurement of Cytokine Production.
 
The pro-
liferative response of purified CD8
 
 
 
 T cells was determined by
measurement of [
 
3
 
H]thymidine (Amersham Pharmacia Biotech)
incorporation after 3 d. IC
 
50
 
 values were calculated by nonlinear
regression.
ELISAs were performed using purified anti–IFN-
 
 
 
 or anti–
IL-2 mAb (2 
 
 
 
g/ml), biotinylated anti-IFN-
 
 
 
 or anti–IL-2
mAb, horseradish peroxidase–conjugated avidin D (2.5 
 
 
 
g/ml;
Vector Laboratories), peroxidase substrate and reaction stop so-
lutions (Kirkegaard and Perry Laboratories, Inc.) following the
recommended protocol (BD PharMingen). Recombinant mouse
IFN-
 
 
 
 (GIBCO BRL) and mouse IL-2 (R&D Systems) were
used as standards. 
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Cell Viability and Terminal Deoxynucleotidyltransferase-mediated
dUTP Nick End-labeling Staining.
 
Apoptosis of total CD8
 
 
 
 T
cells was determined by the terminal deoxynucleotidyltransferase-
mediated dUTP nick end-labeling (TUNEL) assay (BD Phar-
Mingen) following the manufacturer’s recommended protocol.
 
Western Blot Analysis.
 
c-Jun expression was measured by im-
munoblot analysis using a polyclonal antibody raised against or
c-Jun (Cell Signaling Technologies) following the manufacturer’s
protocol. JNK protein levels were measured by immunoblot anal-
ysis using an anti–human JNK mAb (BD PharMingen) (28). Blots
were then stripped and reprobed with an anti-actin mAb (AC40;
Sigma-Aldrich). Immune complexes were detected by enhanced
chemiluminescence (Kirkegaard & Perry Laboratories, Inc.).
 
Protein Kinase Assays.
 
Protein kinase assays were performed as
described (7). Cell lysates were incubated in Triton lysis buffer
(20 mM Tris pH 7.4, 1% Triton X-100, 10% glycerol, 137 mM
NaCl, 2 mM EDTA, 25 mM  -glycerophosphate, 1 mM sodium
orthovanadate, 2 mM pyrophosphate, 1 mM phenylmethylsulfo-
nyl fluoride, 10  g/ml leupeptin) with GST-c-Jun immobilized
on GSH-agarose beads. After 12 h at 4 C, the beads were washed
extensively in lysis buffer followed by kinase assay buffer (25 mM
HEPES pH 7.4, 25 mM  -glycerophosphate, 25 mM MgCl2, 0.1
mM sodium orthovanadate, 0.5 mM DTT) and the activity of the
bound JNK was detected by the addition of [ -32P]ATP for 30
min at 30 C. The reaction products were resolved by SDS-PAGE
and the incorporation of [32P]phosphate was quantitated by Phos-
phorImager analysis (Molecular Dynamics).
Northern Blot Analysis and Ribonuclease Protection Assays. To-
tal RNA from CD8  T cells was isolated using the Ultraspec
RNA isolation reagent (Biotecx Laboratory) as recommended by
the manufacturer. 7  g of RNA was examined by Northern blot
as described previously (45). Specific cDNA probes for Jnk1 and
Jnk2 (28) were labeled with [32P]dCTP using the Random
Primer Kit (Stratagene).
Total RNA was extracted as above. 2–3  g of total RNA was
examined by ribonuclease protection assay (RPA) using
[32P]UTP-labeled RNA probes transcribed in vitro from mCK-1
and mCR-3 DNA templates provided in the RPA kit following
the manufacturer’s recommended protocol (BD PharMingen).
Nuclear Extracts and Electrophoretic Mobility Shift Assays. Nu-
clear extracts from CD8  T cells or CD4  T cells (2–3   106)
were made as described previously (46, 47). Binding reactions for
the electrophoretic mobility shift assays (EMSAs) were performed
using 2  g of nuclear protein and a [32P]dCTP-end-labeled dou-
ble strand oligonucleotide as described previously (43). The oli-
gonucleotides used in this study are as follows: activating protein
1 (AP-1) (5 -GTCGACGTGAGTCAGCGCGC-3 ) (48, 49);
IL-4-NFAT (5 -GTAATAAAATTTTCCAATGTAAA-3 ) (50);
cyclic AMP-responsive element (CRE) (5 -GATCTCTCT-
GACGTCAGCCAAGGAGGAGGCC-3 ) (51); and IL-2R /
AP-1(5 -GCTTTGTTGAGTCTTCTGG-3 ) (52). 2  l/reac-
tion of anti-Jun family rabbit antiserum was used per reaction in
competition studies.
Luciferase Activity. Luciferase activity in cell extracts was mea-
sured as described previously (53) using the Luciferase Assay kit
(Promega).
Results
Normal Viral Immune Response in JNK2-deficient Mice.
We have previously shown that CD4  T cells from JNK2-
deficient (Jnk2 / ) mice had reduced IFN-  production
and impaired Th1 differentiation in vitro whereas Th2 dif-
ferentiation was unaffected (34). To determine whether
JNK2 was required for a Th1 immune response in vivo,
wild-type and Jnk2 /  mice were intranasally inoculated
with the HKx31 strain of the human influenza virus. Both
wild-type and Jnk2 /  mice developed nonfatal pneumo-
nia and displayed clinical signs of infection characterized by
anorecticism, increased respiratory rates, ruffled fur, and
grayish atelectatic areas on the lungs (data not shown). Fur-
thermore, the size of the mediastinal lymph node increased
in both wild-type and Jnk2 /  mice after infection (data
not shown). To examine virus titers, lung tissue was har-
vested from wild-type and Jnk2 /  mice at different time
points following the intranasal inoculation with HKx31.
The virus titers in the lung tissue of Jnk2 /  mice were
similar to those observed in wild-type mice at the peak of
infection (day 4; Fig. 1 A). Moreover, similar levels of vi-
rus-specific IgG1 and IgG2A antibodies were detected in
the serum of infected Jnk2 /  and wild-type mice (Fig. 1,
B and C). Thus, despite the impaired Th1 differentiation in
vitro, the absence of JNK2 did not interfere with the in
vivo antiviral immune response.
Figure 1. In vivo viral im-
mune response in the JNK2-
deficient mice. (A) Virus titers in
the lung tissue of infected wild-
type (WT) and Jnk2 /  mice
were determined at different
time points during influenza in-
fection. Open circles represent
individual infected wild-type
mice; filled circles represent indi-
vidual infected Jnk2 /  mice;
(X) represents the geometric
mean for wild-type mice; (*)
represents the geometric mean
for Jnk2 /  mice. (B and C) Se-
rum was collected from infected
wild-type and Jnk2 /  mice at
different time points during in-
fluenza infection. Virus-specific
IgG1 (B) and virus-specific
IgG2A (C) Ab levels were deter-
mined by ELISA.814 JNK and CD8  T Cell Activation
Regulation of the JNK2 During CD8  T Cell Activation.
CD4  T cells play an important role in mediating the anti-
viral immune response. However, during the influenza in-
fection in mice, CD8  T cells play a critical role in viral
clearance from the host during the influenza infection. As
the function of JNK2 in CD8  T cells remained unknown,
it was possible that the presence of functional CD8  T cells
in the Jnk2 /  mice compensated for their impaired Th1
response. To investigate the role of JNK2 in CD8  T cells,
we examined JNK activity in CD8  T cells isolated from
wild-type mice in response to stimulation with anti-CD3
and anti-CD28 mAbs. Similar to the delayed kinetics of
JNK activation in CD4  T cells (28), activation of JNK in
CD8  T cells required long periods of stimulation ( 24 h;
Fig. 2 A). We have previously shown that the delayed ki-
netics of JNK activation in CD4  T cells was due to the
low level of JNK1 and JNK2 proteins in freshly isolated
cells and upregulation of Jnk1 and Jnk2 gene expression af-
ter stimulation (28). To determine whether the increase in
JNK activity in activated CD8  T cells correlated with in-
creased Jnk1 and Jnk2 gene expression, we examined Jnk1
and Jnk2 mRNA levels in CD8  T cells after stimulation
with anti-CD3 and anti-CD28 mAbs by Northern blot
analysis. Low levels of Jnk1 and Jnk2 mRNA were present
in freshly isolated CD8  T cells while high levels of Jnk1
and Jnk2 mRNA were found in activated CD8  T cells
(Fig. 2 B). In correlation, high levels of JNK1 and JNK2
protein were present in activated CD8  T cells (Fig. 2 C).
To determine whether JNK2 contributed to the JNK
activity observed in CD8  T cells, we examined total JNK
activity in CD8  T cells isolated from wild-type and Jnk2 / 
mice activated with anti-CD3 and anti-CD28 mAbs. Re-
duced levels of JNK activity were observed in activated
CD8  T cells from Jnk2 /  mice compared with activated
wild-type CD8  T cells (Fig. 2 D). These data indicated
that JNK2 contributed to the total JNK activity in CD8  T
cells and that the presence of JNK1 did not completely
compensate for the absence of JNK2.
JNK2 Is a Negative Regulator of CD8  T Cell Activation.
To determine whether the lack of JNK2 could affect
CD8  T cell activation, we examined the proliferative re-
sponse of Jnk2 /  CD8  T cells. Increased proliferation of
Jnk2 / CD8  T cells was observed compared with wild-
type CD8  T cells after activation with anti-CD3 and anti-
CD28 mAbs (Fig. 3 A). Despite the high rate of prolifera-
tion, no differences in the surface expression of activation
markers (CD25 [IL-2R ], CD69, CD44) were observed
between activated wild-type and Jnk2 /  CD8  T cells
(data not shown). Increased proliferation was also observed
when Jnk2 / CD8  T cells were activated with Concava-
lin A and antigen-presenting cells (data not shown). In cor-
relation with our in vitro results, increased expansion of
CD8  T cells in Jnk2 /  mice has also been observed dur-
ing the lymphocytic choriomeningitis virus (LCMV) infec-
tion in vivo (Arbour et al. in this issue [53a]).
Previous studies have demonstrated that the activation of
JNK signaling pathway is implicated in cell death (for a re-
view, see reference 4). We examined whether the in-
creased proliferation of CD8  T cells from Jnk2 /  mice
was due to increased resistance of these cells to activation-
induced death. CD8  T cells from wild-type and Jnk2 / 
mice were activated with anti-CD3 and anti-CD28 mAbs
and cell death was determined by the TUNEL assay. Simi-
lar percentages of apoptotic cells were observed in freshly
isolated and activated wild-type and Jnk2 /  CD8  T cell
populations (Fig. 3 B). These data indicated that the ab-
sence of JNK2 did not affect the ability of these cells to un-
dergo cell death.
IL-2 is the major growth factor for CD8  T cells. IL-2
is also produced by CD8  T cells but to a much lesser ex-
tent than CD4  T cells. It was therefore possible that the
increased proliferation of Jnk2 / CD8  T cells resulted
Figure 2. Activation of the JNK signaling pathway
in CD8  T cells. (A) Total CD8  T cells (106 cells/ml)
from wild-type mice were stimulated with immobi-
lized anti-CD3 (5  g/ml) and soluble anti-CD28 (1
 g/ml) mAbs. Cells were harvested at the indicated
time points, lysed, and cell extracts were assayed for
JNK activity. Phosphorylated c-Jun was detected after
SDS-PAGE by autoradiography. (B) Jnk expression
was examined by Northern blot in CD8  T cells stimu-
lated as in A for the indicated time periods. Expression
of 28S ribosomal RNA was used as a control. (C) JNK
expression was examined by Western blot analysis in
CD8  T cells stimulated as in A for the indicated time
periods. Actin expression was used as a control. (D)
JNK activity was determined using cell extracts from
freshly isolated (-) wild-type (WT) and Jnk2 /  CD8 
T cells and wild-type and Jnk2 /  CD8  T cells stimu-
lated as in A for 48 h.815 Conze et al.
from increased production of IL-2. We therefore exam-
ined the IL-2 production by CD8  T cells isolated from
wild-type and Jnk2 /  mice. Activated CD8  T cells
from  Jnk2 /  mice produced increased levels of IL-2
compared with activated CD8  T cells from wild-type
mice (Fig. 3 C). To determine whether the increased
amount of IL-2 detected in the culture supernatant was
due to increased production of IL-2 rather than reduced
consumption, we examined IL-2 gene expression by an
RPA. IL-2 mRNA was not detected in freshly isolated
wild-type and Jnk2 / CD8  T cells despite similar
mRNA levels of the housekeeping genes L32 and
GAPDH (Fig. 3 D). However, increased levels of IL-2
mRNA were detected in activated CD8  T cells from
Jnk2 /  mice compared with activated wild-type CD8  T
cells (Fig. 3 D) while the levels of L32 and GAPDH
mRNA were similar (Fig. 3 D). A slight increase in the
expression of IFN-  mRNA was also detected in acti-
vated  Jnk2 / CD8  T cells compared with activated
wild-type CD8  T cells (Fig. 3 D). In correlation, higher
amounts of IFN-  were detected in the culture superna-
tant of activated Jnk2 / CD8  T cells (Fig. 3 E).
To determine whether the higher rate of proliferation
observed in Jnk2 / CD8  T cells compared with wild-type
CD8  T cells was due to the amount of IL-2 produced
during activation, we examined the proliferative response of
wild-type and Jnk2 / CD8  T cells activated in the pres-
ence of exogenous IL-2. Similar amounts of proliferation
were observed in wild-type and Jnk2 / CD8  T cells (Fig.
3 F) in these conditions. Moreover, the presence of a neu-
tralizing anti-IL-2 mAb during the activation of these cells
abolished the hyperproliferation of Jnk2 / CD8  T cells
(Fig. 3 F). Together, these data indicated that JNK2 defi-
ciency caused increased production of IL-2 and subsequent
hyperproliferation of activated CD8  T cells.
Impaired Proliferation of Jnk1 / CD8  T Cells. Both
JNK1 and JNK2 are expressed at low levels in resting
CD4  T cells and high levels in activated CD4  (28).
While JNK2 is required for IFN-  production by CD4  T
cells (34), JNK1 negatively regulates IL-4 production by
CD4  T cells (35). These studies indicate that these two
isoforms control different aspects of CD4  T cell effector
function. To determine whether these two kinases also
have distinct functions in CD8  T cells, we examined
JNK1-deficient CD8  T cells. We first examined JNK ac-
tivity in activated CD8  T cells from wild-type and Jnk1 / 
mice stimulated with anti-CD3 and anti-CD28 mAbs.
Unlike wild-type CD8  T cells, very low levels of JNK ac-
tivity were detected in Jnk1 / CD8  T cells (Fig. 4 A). In-
terestingly, the reduction in JNK activity in activated
Figure 3. JNK2 is a negative regulator of CD8  T cells activation. (A) Total CD8  T cells (2.5   105 cells/ml) from wild-type (WT) and Jnk2 /  mice
were stimulated with immobilized anti-CD3 (5  g/ml) alone or in combination with soluble anti-CD28 (1  g/ml) mAbs. The proliferative response was
examined by [3H]thymidine incorporation. (B) Cell death determined by the TUNEL assay in freshly isolated (unstimulated) wild-type and Jnk2 /  CD8 
T cells and wild-type and Jnk2 /  CD8  T cells (106 cells/ml) stimulated with anti-CD3 (5  g/ml) and soluble anti-CD28 (1  g/ml) mAbs for 24 h.
Numbers represent the percentage of TUNEL-positive cells. TdT, terminal deoxynucleotidyltransferase. (C) Wild-type and Jnk2 /  CD8  T cells were
stimulated as described in B for 48 h IL-2 production was determined by ELISA. (D) Cytokine gene expression was determined by RPA using RNA ex-
tracted from freshly isolated ( ) Wild-type and Jnk2 /  (J2) CD8  T cells and wild-type and J2 CD8  T cells stimulated ( ) as described in B for 24 h (E)
Wild-type and Jnk2 /  CD8  T cells were stimulated as in B for 48 h IFN-  production was determined by ELISA. (F) CD8  T cells from wild-type and
Jnk2 /  mice (2.5   105 cells/ml) were stimulated with immobilized anti-CD3 (5  g/ml) and soluble anti-CD28 (1  g/ml) mAb in the presence of ex-
ogenous IL-2 (50 U/ml) or a neutralizing anti-IL-2 (10  g/ml) mAb. The proliferative response was analyzed by [3H]thymidine incorporation.816 JNK and CD8  T Cell Activation
Jnk1 / CD8  T cells compared with wild-type CD8  T
cells (Fig. 4 A) was greater than the reduction observed in
activated Jnk2 / CD8  T cells (Fig. 2 D). These data sug-
gested that JNK1 was the predominant contributor to the
total JNK activity in CD8  T cells.
To determine whether the effects of JNK1-deficiency
on CD8  T cell proliferation were similar to JNK2-defi-
ciency, we compared the proliferation of wild-type and
Jnk1 / CD8  T cells. In contrast to Jnk2 / CD8  T cells,
the proliferative response of Jnk1 / CD8  T cells was sub-
stantially impaired in response to either anti-CD3 mAb
alone or anti-CD3 plus anti-CD28 mAbs (Fig. 4 B). Simi-
lar percentages of apoptotic CD8  T cells were observed
after the activation of wild-type and Jnk1 / CD8  T cells
with anti-CD3 and anti-CD28 mAbs (Fig. 4 C), indicating
that the hypoproliferation of these cells was not due to in-
creased cell death. Together these data show that JNK1 was
required for CD8  T cell expansion in vitro. Arbour et. al.
have also shown that JNK1 is required for the expansion of
virus specific CD8  T cells in vivo (53a).
Mice with compound deficiencies of JNK1 and JNK2
die in utero (37, 38). As an alternative approach to address
how the absence of JNK activity affects the activation of
CD8  T cells, we examined the effect of a newly de-
scribed pharmacological compound (SP600125), which
inhibits both JNK1 and JNK2 (54). Activation of wild-
type CD8  T cells in the presence of different concentra-
tions of the JNK inhibitor caused a dose-dependent inhibi-
tion of proliferation (IC50   3.4  M; Fig. 4 D). Complete
inhibition of proliferation with 10  M, however, could be
due to nonspecific effects of the inhibitor on other signal-
ing pathways. CD8  T cells activated in the presence of
the JNK inhibitor behaved like the Jnk1 / CD8  T cells,
indicating that the function of JNK1 predominates over
the function of JNK2. Thus, while JNK2 appears to be a
negative regulator for CD8  T cells, JNK1 is required for
CD8  T cell activation.
To determine whether JNK-deficiency could affect the
effector function of CD8  T cells, we examined the
amount of IL-2 and IFN-  produced by CD8  T cells iso-
lated from wild-type and Jnk1 /  mice. In correlation with
their inability to undergo activation-induced expansion,
Jnk1 / CD8  T cells produced lower amounts of IL-2 and
IFN-  compared with activated wild-type CD8  T cells
(Fig. 5 A). Activation of wild-type CD8  T cells in the
presence of different concentrations of the JNK inhibitor
caused a dose-dependent inhibition of IL-2 production
(Fig. 5 B).
It was possible that the lower amounts of IL-2 produced
by activated Jnk1 / CD8  T cells accounted for their im-
paired proliferation. To determine whether IL-2 could res-
cue the low levels of proliferation of these cells, we exam-
ined the proliferative response of Jnk1 / CD8  T cells
activated in the presence of exogenous IL-2. Despite satu-
rating levels of IL-2, the proliferation of activated Jnk1 / 
CD8  T cells remained reduced compared with activated
wild-type CD8  T cells (Fig. 5 C). In correlation, the pres-
ence of exogenous IL-2 did not prevent the inhibition of
CD8  T cell proliferation caused by the JNK inhibitor
(IC50   7.4  M; Fig. 5 D). Thus the impaired proliferation
of Jnk1 / CD8  T cells was not due to low levels of IL-2
produced by these cells.
JNK1 Is Required for IL-2 Receptor   Chain Expression.
The inability of exogenous IL-2 to restore the reduced
proliferation of Jnk1 / CD8  T cells suggested that JNK1
could be required for IL-2 receptor expression. We exam-
ined the cell surface expression of the   chain of the IL-2
receptor (IL-2R /CD25) by flow cytometry on wild-type
and  Jnk1 / CD8  T cells activated with anti-CD3 and
anti-CD28 mAbs. The percentage of activated Jnk1 / 
CD8  T cells that expressed IL-2R  was significantly re-
duced compared with activated wild-type CD8  T cells
(Fig. 6 A). Moreover, the mean fluorescence intensity of
IL-2R  on Jnk1 / CD8  T cells was substantially lower
Figure 4. JNK1 is required for CD8  T cell acti-
vation. (A) JNK activity was determined using cell
extracts from freshly isolated ( ) wild-type (WT)
and  Jnk1 /  CD8  T cells and wild-type and
Jnk1 /  CD8  T cells (106 cells/ml) stimulated
with immobilized anti-CD3 (5  g/ml) and soluble
anti-CD28 (1  g/ml) mAbs for 48 h (B) CD8  T
cells (2.5   105 cells/ml) from wild-type and Jnk1 / 
mice were stimulated with anti-CD3 alone or in
combination with soluble anti-CD28 mAbs. The
proliferative response was examined by [3H]thymi-
dine incorporation. (C) Cell death determined by
the TUNEL assay in freshly isolated (unstimulated)
wild-type and Jnk1 /  CD8  T cells and wild-type
and Jnk1 /  CD8  T cells (106 cells/ml) stimulated
as in A for 24 h. Numbers represent the percentages
of TUNEL-positive cells. TdT, terminal deoxynu-
cleotidyltransferase. (D) Wild-type CD8  T cells
were stimulated as in B in the presence of different
concentration of the JNK inhibitor (SP600125).
The proliferative response was examined by
[3H]thymidine incorporation. An IC50 was calcu-
lated by nonlinear regression (IC50   3.4  M).817 Conze et al.
than the mean fluorescence intensity on wild-type CD8  T
cells (Fig. 6 A). Reduced expression of IL-2R  in Jnk1 / 
CD8  T cells was also observed even in the presence of ex-
ogenous IL-2 (data not shown). In correlation, IL-2R  cell
surface expression on wild-type CD8  T cells activated in
the presence of the JNK inhibitor was also substantially re-
duced (Fig. 6 B).
To determine whether the reduced cell surface expres-
sion of IL-2R  on activated Jnk1 / CD8  T cells was due
to impaired IL-2R  gene expression, we examined IL-
2R  chain mRNA levels by RPA using RNA extracted
from activated wild-type and Jnk1 / CD8  T cells. Con-
sistent with the reduced levels of IL-2R  on the surface of
Jnk1 / CD8  T cells, the levels of IL-2R  mRNA in ac-
tivated Jnk1 / CD8  T cells were also substantially lower
than the levels detected in wild-type CD8  T cells (Fig. 6
C). No significant differences in IL-2R  or the  c chain
mRNA were observed between activated wild-type and
Jnk1 / CD8  T cells (Fig. 6 C), indicating the JNK1 was
specifically required for the expression of the IL-2R  chain
in CD8  T cells.
Unstimulated T cells do not express IL-2R  gene. After
TcR ligation, IL-2R  gene expression is induced and sub-
sequently upregulated in response to IL-2. To determine
whether JNK1 was required for TcR-mediated upregula-
tion of the IL-2R  gene, we examined IL-2R  gene ex-
pression in wild-type and Jnk1 / CD8  T cells activated in
the presence of a neutralizing anti–IL-2 mAb to prevent
IL-2–induced upregulation of the IL-2R . Even in the
presence of the anti–IL-2 mAb the levels of expression of
IL-2R  gene were significantly reduced in activated Jnk1 / 
CD8  T cells compared with activated wild-type CD8  T
cells (Fig. 6 D). In contrast, normal levels of IL-2R 
mRNA were found in activated Jnk2 / CD8  T cells (Fig.
6 D). Thus, JNK1 was required for TcR-induced IL-2R 
gene expression.
The impaired expression of IL-2R  in Jnk1 / CD8  T
cells could explain the hypoproliferation of these cells.
Could the impaired expression of IL-2R  also explain the
inability of Jnk1 / CD8  T cells to produce IL-2 and
IFN- ? We first examined the effect of exogenous IL-2 on
the expression of these genes during the activation of wild-
type CD8  T cells. The presence of exogenous IL-2
caused a dramatic increase of IFN-  mRNA levels and a
moderate increase in IL-2 mRNA levels (Fig. 6 E). To de-
termine whether the low levels of IL-2R  on the surface
of Jnk1 / CD8  T cells could prevent the upregulation of
IL-2 and IFN-  gene expression by IL-2, we examined cy-
tokine mRNA levels in Jnk1 / CD8  T cells activated in
the presence of exogenous IL-2. Unlike activated wild-
type CD8  T cells, Jnk1 / CD8  T cells contained low
levels of IFN-  and nearly undetectable levels of IL-2
mRNA (Fig. 6 F). Together these results support the im-
paired expression of IL-2R  on Jnk1 / CD8  T cells as
the primary cause of the hypoproliferation and reduced
production of effector cytokines by these cells.
JNK1 Is Required for AP-1 DNA Binding to the IL-2R 
Promoter in CD8  T Cells. Several substrates of JNK
have been identified. Specifically, JNK has been shown to
regulate the Jun family of proteins and, therefore, the ac-
tivity of the transcription factor AP-1 (2). Two AP-1–like
sites have been identified in the  415– 1 promoter re-
gion of the IL-2R  gene (52) but they have not been well
characterized. To determine whether AP-1 complexes
were able to bind to these AP-1-like sites, we performed
EMSAs using specific oligonucleotides that spanned the
AP-1–like sites from the IL-2R  promoter and nuclear
extracts from activated wild-type CD8  T cells. We could
not detect nuclear complexes bound to the –336 to  321
AP-1–like consensus sequence (GGACTCA) (data not
shown). However, a –365 to –347 oligonucleotide con-
taining the AP-1–like sequence (TGAGTCT) (IL-2R /
Figure 5. IL-2 does not re-
store impaired proliferation of
Jnk1 /  CD8  T cells. (A)
Wild-type (WT) and Jnk1 / 
CD8  T cells (106 cells/ml) were
stimulated with immobilized
anti-CD3 (5  g/ml) and soluble
anti-CD28 (1  g/ml) mAbs for
48 h IL-2 (left panel) and IFN- 
(right panel) production was de-
termined by ELISA. (B) CD8 
T cells (106 cells/ml) from wild-type mice were stimulated
as in A for 48 h in the presence of different concentration
of the JNK inhibitor (SP600125). IL-2 production was de-
termined by ELISA. (C) CD8  T cells from wild-type and
Jnk1 /  mice (2.5   105 cells/ml) were stimulated as in A
in the presence of exogenous IL-2 (50 U/ml). The prolif-
erative response was examined by [3H]thymidine incorpo-
ration. (D) Total CD8  T cells (2.5   105 cells/ml) from
wild-type mice were stimulated as in A in the presence of
different concentrations of the JNK inhibitor and exoge-
nous IL-2. The proliferative response was examined by
[3H]thymidine incorporation. An IC50 was calculated by
nonlinear regression (IC50   7.4  M).818 JNK and CD8  T Cell Activation
AP-1) was able to bind nuclear complexes (Fig. 7 A). In-
terestingly, the level of binding to this IL-2R /AP-1 ele-
ment was reduced in activated JNK1-deficient CD8  T
cells compared with activated wild-type CD8  T cells
(Fig. 7 A). To verify that the complexes bound to the IL-
2R /AP-1 element were indeed AP-1, we performed
competition studies using a cold oligonucleotide contain-
ing an AP-1 consensus sequence from the human collage-
nase promoter (53). The presence of the cold AP-1 oligo-
nucleotide completely abrogated DNA binding to the
IL-2R /AP-1 element (Fig. 7 B). In contrast, cold oligo-
nucleotides containing unrelated consensus sequences such as
those for the transcription factors signal transducer activa-
tor of transcription (STAT; Fig. 7 B) or nuclear factor
(NF) B (data not shown) did not affect the DNA binding
to the IL-2R /AP-1 element. A cold oligonucleotide
containing the consensus CRE, which has homology with
the AP-1 consensus sequence (51), also competed with
the IL-2R /AP-1 DNA binding (Fig. 7 B). Competition
with anti-Jun family antisera confirmed the presence of
Jun family members in the IL-2R /AP-1 complex (Fig. 7
B). In addition, competition with antisera raised against
CRE binding protein (CREB) also showed the presence
of CREB in the IL-2R /AP-1 complex (data not
shown).
To determine whether the reduced IL-2R /AP-1 DNA
binding found in activated Jnk1 / CD8  T cells was due
to reduced amounts of AP-1 or CREB we examined the
DNA binding to consensus AP-1 and CRE DNA regula-
tory sequences. A substantial reduction in the amount of
AP-1 DNA binding was observed in activated Jnk1 / 
CD8  T cells compared with that in activated wild-type
CD8  T cells (Fig. 7 C). In contrast, the levels of CREB
DNA binding in activated Jnk1 / CD8  T cells was not
reduced (Fig. 7 C). Unlike Jnk1 / CD8  T cells, activated
Jnk2 / CD8  T cells had levels of AP-1 and CREB DNA
binding that were similar to those in activated wild-type
CD8  T cells (Fig. 7 C). These results indicated that the
reduced levels of IL-2R /AP-1 DNA binding in Jnk1 / 
CD8  T cells was due primarily to the low levels of nu-
clear AP-1 complexes in these cells. We also examined
NFAT DNA binding and found that NFAT nuclear com-
plexes were increased in activated Jnk1 / CD8  T cells
(Fig. 7 C). These results correlated with the previously de-
scribed negative regulation of NFAT by JNK (25, 55). In
contrast to the reduced levels of nuclear AP-1 observed in
Figure 6. Impaired IL-2R  gene expression in Jnk1 /  CD8  T cells. (A) CD8  T cells from wild-type (WT) and Jnk1 /  mice (106 cells/ml) were
stimulated with immobilized anti-CD3 (5  g/ml) and soluble anti-CD28 (1  g/ml) mAbs for 48 h and stained with anti-IL-2R  (CD25) mAbs. Cell sur-
face expression of IL-2R  was determined by flow cytometry. Numbers represent the percentage of cells in each quadrant. The mean fluorescence inten-
sity for the upper right quadrant of each plot is indicated in bold italics. (B) Cell surface expression of IL-2R  was determined on wild-type CD8  T cells
(106 cells/ml) stimulated as in A in the presence of the JNK inhibitor (SP600125; 5.6  M). (C) Cytokine receptor gene expression was determined by
RPA using RNA extracted from freshly isolated ( ) wild-type and Jnk1 /  (J1) CD8  T cells and wild-type and J1 CD8  T cells stimulated ( ) as in A
for 24 h. (D) Cytokine receptor gene expression was determined by RPA using RNA extracted from wild-type, J1, and Jnk2 /  (J2) CD8  T cells stim-
ulated as in A for 36 h in the presence of a neutralizing anti-IL-2 (10  g/ml) mAb. (E) Cytokine gene expression was determined by RPA using RNA ex-
tracted from wild-type CD8  T cells stimulated as in A in the absence ( ) or presence of exogenous IL-2 (50 U/ml) for 24 h. (F) Cytokine gene expression
was determined by RPA using RNA extracted from wild-type and J1 CD8  T cells stimulated as in A for 24 h in the presence of exogenous IL-2.819 Conze et al.
activated Jnk1 / CD8  T cells, the levels of nuclear AP-1
DNA complexes in activated Jnk1 / CD4  T cells were
normal or slightly increased (Fig. 7 D). CREB DNA bind-
ing was also examined as a control for protein loading (Fig.
7 D). These results indicate that the targets of JNK1 differ
in CD4  and CD8  T cells.
Phosphorylation of Jun family members by JNK has
been shown to regulate AP-1 transcriptional activity but
does not appear to be required for AP-1 DNA binding (7).
Thus, the reduction of AP-1 DNA binding in Jnk1 / 
CD8  T cells could not be directly explained by the lack
of JNK1-mediated phosphorylation. As c-Jun expression is
upregulated by AP-1 (3), it was possible that the reduced
levels of nuclear AP-1 complexes in activated Jnk1 / 
CD8  T cells could be due to decreased levels of c-Jun.
We examined the levels of c-Jun in activated wild-type and
Jnk1 / CD8  T cells by Western blot analysis. c-Jun ex-
pression was induced in activated Jnk1 / CD8  T cells but
delayed compared with the kinetics of c-Jun expression in
activated wild-type CD8  T cells (Fig. 7 E). The levels of
JunD, however, were comparable in wild-type and Jnk1 / 
CD8  T cells (data not shown). The kinetics of c-Jun ex-
pression in activated Jnk2 / CD8  T cells were compara-
ble to those in activated wild-type CD8  T cells (Fig. 7 E).
Together, these results suggested that the reduced expres-
sion of IL-2R  in activated Jnk1 / CD8  T cells was most
likely due to reduced levels of c-Jun in these cells.
To confirm that the reduced AP-1 DNA binding in
Jnk1 / CD8  T cells resulted in impaired AP-1 transcrip-
tional activity, Jnk1 /  mice were backcrossed with AP-1
luciferase reporter transgenic mice (53) and AP-1 transcrip-
tional activity was measured by the luciferase assay. AP-1
transcriptional activity in activated wild-type CD8  T cells
was detected at 40 h and upregulated in a time-dependent
fashion (Fig. 7 F). In contrast, AP-1 transcriptional activity
in activated Jnk1 / CD8  T cells was undetectable until
60 h and dramatically reduced compared with the activity
detected in activated wild-type CD8  T cells (Fig. 7 F).
Thus, JNK1 was required for AP-1 mediated transcription
in CD8  T cells.
Discussion
MAP kinase signaling pathways are implicated in several
biological processes, including growth, differentiation, and
cell death. The ERK signaling pathway has been primarily
associated with cell growth and differentiation whereas the
JNK and p38 MAP kinase signaling pathways have been as-
Figure 7. Reduced  binding
of AP-1 DNA binding in
Jnk1 / CD8  T cells. (A) DNA
binding of transcription factors to
the AP-1–like site in the IL-2R 
promoter (AP-1/IL-2R ) was
determined using nuclear ex-
tracts prepared from wild-type
(WT), and Jnk1 /  (J1) CD8  T
cells stimulated with immobi-
lized anti-CD3 (5  g/ml) and
soluble anti-CD28 (1  g/ml)
mAbs for 36 h and a [32P]-end-
labeled double stranded oligonu-
cleotide spanning –365 to –347
of the IL-2R  promoter. (B)
Composition of the AP-1 com-
plex detected in activated CD8 
T cells. Nuclear extracts were
prepared from wild-type CD8 
T cells stimulated with immo-
bilized anti-CD3 and soluble
anti-CD28 mAbs as in A. DNA
binding to the AP-1/IL-2R  el-
ement was performed in the ab-
sence ( ) or presence of cold
AP-1, STAT, or CRE oligonu-
cleotides. DNA binding to the
AP-1/IL-2R  element was also
examined in the presence of
anti-Jun family ( Jun Family)
antiserum. (C) AP-1, CREB,
and NFAT DNA binding was
determined using nuclear extracts from unstimulated wild-type, J1, and Jnk2 /  (J2) CD8  T cells and wild-type, J1, and J2 CD8  T cells stimulated as
in A using [32P]-end-labeled double stranded oligonucleotides containing either an AP-1, CREB, or NFAT consensus binding site. (D) AP-1 and CREB
DNA binding was determined using nuclear extracts from wild-type and J1 CD4  T cells stimulated with immobilized anti-CD3 (5  g/ml) and soluble
anti-CD28 (1  g/ml) mAbs for 36 h using [32P]-end-labeled double stranded oligonucleotides containing either an AP-1 or CRE consensus sequence.
(E) Western blot of c-Jun and actin in wild-type, Jnk1 / , and Jnk2 / CD8  T cells stimulated as in A for the indicated time periods. (F) CD8  T cells
were isolated from AP-1-luciferase and Jnk1 /    AP-1-luciferase reporter transgenic mice, stimulated with immobilized anti-CD3 and soluble anti-CD28
as in A for different time periods, harvested, and assayed from luciferase activity. UD, undetectable.820 JNK and CD8  T Cell Activation
sociated with cell death and differentiation. The specific
role of each of these pathways, however, ultimately de-
pends on the cell type. The immune system is a complex
organization of cells, each with a specialized function. In
this study we show that the regulatory roles of JNK1 and
JNK2 in CD8  T cells are distinct from the previously de-
scribed function of these two kinases in CD4  T cells.
Three Jnk genes (Jnk1, Jnk2, and Jnk3) that encode for
at least 10 different isoforms have been identified (2, 4).
Although these isoforms may have different affinities for
specific substrates, no clear specificity has been found. Are
these kinases redundant within the same cell type? Jnk3
is predominantly expressed in heart, brain, and testis
whereas Jnk1 and Jnk2 are widely expressed with the ex-
ception of spleen and lymph nodes (27, 28). Disruption of
Jnk3 in mice causes the failure of hippocampal neurons to
undergo apoptosis in response to excitotoxic stress (27).
In this case, the presence of JNK1 and JNK2 does not
compensate for the lack of JNK3. Similarly, the absence
of both JNK1 and JNK2 during neuronal tube formation
cannot be compensated for by the presence of JNK3 (37,
38). Here, we show that the absence of JNK1 is not com-
pletely compensated for by JNK2 in CD8  T cells. Like-
wise, the absence of JNK2 is not completely compensated
for by JNK1. Similar results have been found in CD4  T
cells (34, 35). Thus, if there is some redundancy of these
kinases, it is limited and depends on the specific tissue or
cell type.
Do JNKs regulate similar biological functions in specific
cell types? It has been shown that a mixed population of
lymphocytes containing both CD4  and CD8  T cells
from either Jnk1 /  or Jnk2 /  mice hypoproliferate and
produce lower levels of IL-2 in response to TcR engage-
ment and suboptimal doses of costimulatory signals (31,
32). Together, these results suggest that JNK1 and JNK2
may have similar functions. However, analysis of CD4  T
cells in these mice has shown that the absence of JNK1 re-
sults in increased Th2 cytokine production (35) whereas
the absence of JNK2 impairs Th1 differentiation (34).
These results indicate that JNK1 and JNK2 have distinct
functions in CD4  T cell differentiation. In this study we
show that Jnk2 /  CD8  T cells hyperproliferate and se-
crete increased amounts of IL-2, while Jnk1 /  CD8  T
cells have impaired expression of IL-2R  expression and
thereby hypoproliferate following TcR ligation. Thus,
JNK1 and JNK2 regulate different aspects of CD8  T cell
function. In correlation with these results, the cosubmitted
study (53a) demonstrates that JNK1 and JNK2 also play
distinct roles in vivo since they differentially regulate T cell
expansion during the LCMV infection. Specifically, im-
paired expansion of LCMV-specific CD8 T  cells was ob-
served in JNK1-deficient mice compared with wild-type
mice while increased expansion of LCMV-specific CD8 
T cells was observed in JNK2-deficient mice (Arbour et al.
in this issue [53a]). Together our results, therefore, demon-
strate that the JNK signaling pathway does indeed play dif-
ferent roles in CD4  and CD8  T cell activation and dif-
ferentiation. Previous studies showing that other signaling
pathways also differentially regulate CD4  and CD8  T
cell activation confirm our findings (56–59).
Like CD4  T cells, CD8  T cells synthesize and secrete
IL-2 upon activation, but the levels and kinetics of IL-2
production are lower and delayed, respectively. Although
IL-2 production is reduced in the Jnk1 /  CD8  T cells,
this is not the major cause of the hypoproliferation of these
cells because exogenous IL-2 did not restore the prolifera-
tion of these cells to normal levels. A critical event required
for the expansion of CD8  T cells after activation is the
upregulation cell surface expression of the IL-2 receptor
(IL-2R)   chain and its association with   and   chains to
form the high affinity IL-2R (   ) (for a review, see refer-
ence 60). Here we show that IL-2R  gene expression is
severely compromised in activated Jnk1 / CD8  T cells.
Several regulatory elements within the IL-2R  pro-
moter such as those for NF B, Elf, HMG-I(Y), and NFAT
have been described (52, 61–63). NF B and Elf DNA
binding were not affected by the lack of JNK1 in CD8  T
cells (data not shown). In correlation with the negative reg-
ulation of NFAT by JNK (55), we observed increased
NFAT DNA binding in activated Jnk1 / CD8  T cells.
Two AP-1 like consensus sites have also been identified
within the proximal IL-2R  promoter (52). Here we show
that AP-1 can bind to one of these elements (IL-2R /AP-1)
and is reduced in JNK1-deficient CD8  T cells. Based on
our results, we propose that the reduced expression of
IL-2R  in Jnk1 /  CD8  T cells is due to reduced levels
of c-Jun and AP-1–mediated transcription. Interestingly,
this effect is also specific to CD8  T cells because IL-2R 
expression (35) and AP-1 DNA binding was not affected in
JNK1-deficient CD4  T cells.
Considering the distinct roles of the different JNK fam-
ily members in CD4  and CD8  T cell activation and dif-
ferentiation, predicting the final outcome of an in vivo
immune response in mice deficient of JNK1 or JNK2
could be difficult. Consistent with the predominant Th2
bias of Jnk1 / CD4  T cells in vitro, JNK1-deficient mice
fail to resolve the Leishmania major infection (36) which re-
quires CD4  Th1 effector cells for pathogen clearance
(64). In contrast, despite impaired CD4  Th1 differentia-
tion observed in vitro (34), JNK2-deficient mice are able
to resolve the influenza infection (Fig. 1 A) which requires
both effector Th1 and CD8  T cells for viral clearance.
The increased expansion and production of IFN-  by
Jnk2 / CD8  T cells shown here could compensate for
the impaired Th1 differentiation in vivo and account for
the normal viral clearance observed in these mice. En-
hanced CD8  T cell expansion in Jnk2 /  while impaired
expansion of CD8  T cells in Jnk1 /  mice during the
LCMV infection have been described (53a). Together,
these results are consistent with our in vitro studies show-
ing that JNK1-deficient CD8  T cells hypoproliferate af-
ter TcR ligation due to impaired IL-2R  expression
whereas JNK2-deficient CD8  T cells hyperproliferate af-
ter TcR ligation. Our studies support the distinct roles for
JNK1 and JNK2 in CD8  T cell activation both in vitro
and in vivo.821 Conze et al.
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